jan 1, 1996 - Copaxone
Description:
Developed by scientists at the Weizmann Institute and later commercialized by Teva, Copaxone received U.S. FDA approval in 1996 for treating relapsing forms of multiple sclerosis. It became one of the world’s major MS therapies and demonstrated Israel’s ability to transform basic scientific research into globally used medicines, helping strengthen the country’s biotechnology and pharmaceutical industries.Added to timeline:
Date:
jan 1, 1996
Now
~ 30 years ago